losartan has been researched along with Overweight in 2 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Full-dose RAAS inhibition, particularly with perindopril, effectively reduces BP, improves arterial structure and regulates cardiovascular risk factors in overweight or obese patients with hypertension." | 9.17 | Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. ( Barykina, IN; Chumachok, EV; Ledyaeva, AA; Mazina, G; Nedogoda, SV; Salasyuk, AS; Tsoma, VV, 2013) |
| "Full-dose RAAS inhibition, particularly with perindopril, effectively reduces BP, improves arterial structure and regulates cardiovascular risk factors in overweight or obese patients with hypertension." | 5.17 | Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension. ( Barykina, IN; Chumachok, EV; Ledyaeva, AA; Mazina, G; Nedogoda, SV; Salasyuk, AS; Tsoma, VV, 2013) |
| "8 years randomized treatment in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) echocardiography substudy." | 5.17 | Impact of overweight and obesity on cardiac benefit of antihypertensive treatment. ( Boman, K; Dahlöf, B; de Simone, G; Devereux, RB; Gerdts, E; Lund, BP; Nieminen, MS; Okin, PM; Wachtell, K, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nedogoda, SV | 1 |
| Ledyaeva, AA | 1 |
| Chumachok, EV | 1 |
| Tsoma, VV | 1 |
| Mazina, G | 1 |
| Salasyuk, AS | 1 |
| Barykina, IN | 1 |
| Gerdts, E | 1 |
| de Simone, G | 1 |
| Lund, BP | 1 |
| Okin, PM | 1 |
| Wachtell, K | 1 |
| Boman, K | 1 |
| Nieminen, MS | 1 |
| Dahlöf, B | 1 |
| Devereux, RB | 1 |
2 trials available for losartan and Overweight
| Article | Year |
|---|---|
Randomized trial of perindopril, enalapril, losartan and telmisartan in overweight or obese patients with hypertension.
Topics: Adult; Antihypertensive Agents; Benzimidazoles; Benzoates; Blood Pressure; Enalapril; Female; Humans | 2013 |
Impact of overweight and obesity on cardiac benefit of antihypertensive treatment.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Body Mass Index; Body Weight; Doub | 2013 |